Alum’s company gets FDA approval for cancer therapy
Therapeutic oncology company RefleXion Medical has received U.S. Food and Drug Administration (FDA) clearance for a cutting-edge treatment for early and late-stage cancers.
Founded by Dr. Samuel Mazin (BASc ’02, computer engineering) in 2009, RefleXion’s mission is to advance innovative treatment in cancer care through a biology-guided radiotherapy (BgRT) it calls SCINTIX™.